|07th December,2021||12 am||Plenière|
The increasing digitalisation and consumerisation of healthcare, along with changing reimbursement models and care delivery pathways, have created opportunities to generate value for MedTech not only through the manufacture and sale of products, but also through the development of more holistic and data-driven solutions.
To what extent does this transition affect the way R&D efforts are led and MedTech companies go-to market model? How can the right financial and clinical stakeholders be identified early in the development to generate evidence and demonstrate the value of innovative products and services? To what extent does this influence MedTech companies’ collaboration choices?